Results 181 to 190 of about 2,544,276 (249)

As-Needed Medication Use for Agitation Across Valproic Acid Formulations. [PDF]

open access: yesCurr Ther Res Clin Exp
Ley M   +3 more
europepmc   +1 more source

Transcranial Magnetic Stimulation as a Translational Biomarker in Early‐Phase Anti‐Seizure Medication Development: A Randomized, Double‐Blind, Placebo‐Controlled Study in Generalized Epilepsy

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 673-683, September 2026.
One‐third of epilepsy patients remain treatment‐resistant, underscoring the need for novel anti‐seizure medications (ASMs) and reliable biomarkers of central target engagement. Cortical hyperexcitability is a hallmark of epilepsy, making excitability a valuable pharmacodynamic biomarker for early‐phase drug development supporting go/no‐go decision ...
Catherine M. E. de Cuba   +7 more
wiley   +1 more source

Reducing Exposure Before Birth: An Interrupted Time Series Study of Prenatal Exposure to Fetotoxic Medications Under Risk Management Plans in Canada

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 721-730, September 2026.
Canada's 2009 risk management plan (RMP) framework has not been evaluated for prenatal exposure impact. Conversely, widely used drugs such as nonsteroidal anti‐inflammatory drugs (NSAIDs) lack RMPs. We assessed first‐trimester exposure to RMP‐regulated medications following regulatory interventions and to NSAIDs following safety publications.
Nahiyan Saiyara Khan   +4 more
wiley   +1 more source

Diagnosis and management guidelines for infantile epileptic spasms syndrome around the world: A scoping review and comparative study of international approaches

open access: yesEpilepsia, Volume 67, Issue 9, Page 4600-4617, September 2026.
Abstract Objective Infantile epileptic spasms syndrome (IESS) is an epileptic encephalopathy requiring rapid diagnosis and treatment to optimize neurodevelopmental outcomes. Although multiple national and regional guidelines exist, recommendations vary.
Gozde Erdemir   +21 more
wiley   +1 more source

Effectiveness and tolerability of fenfluramine in pediatric and adult patients with developmental and epileptic encephalopathies: A multicenter, retrospective, real‐world clinical‐practice study

open access: yesEpilepsia, Volume 67, Issue 9, Page 4536-4550, September 2026.
Abstract Objective Developmental and epileptic encephalopathies (DEEs) are characterized by drug‐resistant seizures and developmental slowing/regression. We examined the efficacy and tolerability of fenfluramine (FFA) in pediatric and adult patients with Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and other DEEs.
Vicente Villanueva   +29 more
wiley   +1 more source

SUDEP and mortality in developmental and epileptic encephalopathies: A meta‐analysis of randomized clinical trials and extension studies

open access: yesEpilepsia, Volume 67, Issue 9, Page 4631-4648, September 2026.
Abstract Objective Developmental and epileptic encephalopathies (DEEs) are associated with high premature mortality and increased risk of sudden unexpected death in epilepsy (SUDEP). However, epidemiological data remain limited, particularly for specific syndromes such as Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and infantile epileptic ...
Pierludovico Moro   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy